NasdaqCM - Nasdaq Real Time Price USD
Immunome, Inc. (IMNM)
8.50
+0.31
+(3.79%)
At close: April 23 at 4:00:01 PM EDT
8.22
-0.28
(-3.29%)
Pre-Market: 4:18:31 AM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Clay B. Siegall Ph.D. | Chairman, President & CEO | 1.43M | -- | 1961 |
| Dr. Jack Higgins Ph.D. | Chief Scientific Officer | 956.34k | -- | 1980 |
| Dr. Robert J. Lechleider M.D. | Chief Medical Officer | 512.49k | -- | 1962 |
| Mr. Max Rosett | Chief Financial Officer | -- | -- | 1990 |
| Dr. Philip Tsai | Chief Technical Officer | -- | -- | -- |
| Ms. Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel & Corporate Secretary | 443.43k | -- | 1974 |
| Mr. Kinney Horn | Chief Business Officer | -- | -- | 1975 |
| Mr. Roee Shahar | Executive Vice President of Commercial | -- | -- | -- |
Immunome, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 118
Description
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Corporate Governance
Immunome, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 10. The pillar scores are Audit: 6; Board: 9; Shareholder Rights: 7; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC
Immunome, Inc. Earnings Date
Recent Events
Related Tickers
SWTX SpringWorks Therapeutics, Inc.
41.21
+1.75%
IMNN Imunon, Inc.
0.8766
+0.53%
COGT Cogent Biosciences, Inc.
4.4700
+3.00%
JANX Janux Therapeutics, Inc.
31.62
+5.36%
TRML Tourmaline Bio, Inc.
17.82
+2.89%
KURA Kura Oncology, Inc.
6.37
+0.95%
APLS Apellis Pharmaceuticals, Inc.
17.49
+0.69%
AKRO Akero Therapeutics, Inc.
39.61
+2.88%
IMVT Immunovant, Inc.
14.45
+1.40%
BCYC Bicycle Therapeutics plc
8.67
-0.69%